Search results
Oct 10, 2021 · Introduction. Safe and effective vaccines against SARS-CoV-2 are critical to ending the pandemic. Two messenger RNA (mRNA) vaccines (BNT162b2, Pfizer-BioNTech; and mRNA-1273, Moderna) were the first SARS-CoV-2 vaccines authorized in the US. 1,2 Large phase 3 trials for BNT162b2 and mRNA-1273 demonstrated that both vaccines were more than 94% effective against symptomatic SARS-CoV-2 infection ...
- Nicola P Klein, Ned Lewis, Kristin Goddard, Bruce Fireman, Ousseny Zerbo, Kayla E Hanson, James G Do...
- 2021
Oct 12, 2021 · ExposuresReceipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2. Main Outcomes and MeasuresIncidence of serious outcomes, including acute myocardial ...
- Nicola P Klein, Ned Lewis, Kristin Goddard, Bruce Fireman, Ousseny Zerbo, Kayla E Hanson, James G Do...
- 2021
Sep 3, 2021 · Nicola Klein, MD, PhD, director, Vaccine Study Center. “The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. The Vaccine Safety Datalink is ideally suited to carry out this important surveillance and we will continue to monitor the safety of all vaccines that protect against COVID-19,” added Klein ...
Mar 1, 2024 · The most recent COVID-19 booster shot reduces adults’ risk of moderate or severe COVID by more than half, according to a new nationwide data study from September 2023 through January 2024, a period of JN.1 variant dominance. The new study is one of the first to evaluate protection provided by the updated shot against COVID-19-associated ...
Oct 27, 2022 · For a subset of individuals with acute COVID-19 disease, symptoms may persist beyond 1 month, with some patients reporting symptoms at least 6 months later. 1 Initially referred to as postacute sequelae of COVID-19 or post–COVID-19 syndrome, 2 this phenomenon is now more commonly described as long COVID. 3 The World Health Organization 4 ...
Monoclonal Antibody Treatment for COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a spike protein on its surface that helps the virus attach and enter human cells. Several monoclonal antibodies have been developed to bind to the spike protein of SARS-CoV-2 and block the virus from invading human cells.
Apr 7, 2023 · “COVID-19 vaccines in general have had very strong effectiveness,” said lead author Nicola Klein, MD, PhD, director of the Kaiser Permanente Vaccine Study Center, part of the Kaiser Permanente Division of Research. “We did see effectiveness drop significantly in teens, though protection increased for those who subsequently received the monovalent booster.
